PUBLISHER: KBV Research | PRODUCT CODE: 1261359
PUBLISHER: KBV Research | PRODUCT CODE: 1261359
Europe Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Country and Growth Forecast, 2022 - 2028
The Europe Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 1.8% CAGR during the forecast period (2022-2028).
GERD reduces chemical clearance because of the bicarbonates in saliva. The importance of esophageal clearance has recently been shown, even in neonates, where it helps to foretell how well PPI medication would work. It was seen that among neonates with longer acid esophageal exposure times, more effective and quick esophageal clearance as measured by impedance-pH monitoring was substantially related to a favorable clinical response to omeprazole anti-reflux medication (AET).
Some GERD patients are known to have delayed gastric emptying, which may promote the backflow of the stomach material. There is no indication of stomach acid hypersecretion in these individuals, even though the mainstay of GERD therapy is using antisecretory medicines to minimize acid reflux. The most aggressive element in identifying mucosal damage or reflux symptoms continues to be acid. Smoking regularly is regarded as a risk factor for the development of GERD.
Individuals in the least poor regions were likelier than adults in the most deprived areas to consume more than 14 units of alcohol in a typical week. Although younger individuals are less likely than any other age group to drink, the research shows that when they do, their consumption is more likely to be greater than that of older persons on their busiest drinking day. According to a 2015 Italian Ministry of Health assessment, 64.5% of Italians over 11 have used alcohol at least once, with men outnumbering women. The rising frequency of people consuming alcohol is expected to increase the prevalence of digestive illnesses like gastroesophageal reflux and drive the market's expansion.
The Germany market dominated the Europe Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $373.3 Million by 2028. The UK market is anticipated to grow at a CAGR of 1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 2.5% during (2022 - 2028).
Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).
Scope of the Study
Market Segments covered in the Report:
By Type
- Antacids
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Blockers
- Pro-kinetic Agents
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- AstraZeneca PLC
- Eisai Co., Ltd.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Medigus Ltd.
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Gastroesophageal Reflux Disease Therapeutics Market, by Type
- 1.4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
- 3.1 Europe Antacids Market by Country
- 3.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
- 3.3 Europe H2 Receptor Blockers Market by Country
- 3.4 Europe Pro-kinetic Agents Market by Country
Chapter 4. Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
- 4.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
- 4.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.2 UK Gastroesophageal Reflux Disease Therapeutics Market
- 4.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.3 France Gastroesophageal Reflux Disease Therapeutics Market
- 4.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
- 4.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
- 4.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
- 4.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
- 4.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
- 4.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
Chapter 5. Company Profiles
- 5.1 Takeda Pharmaceutical Company Limited
- 5.1.1 Company Overview
- 5.1.2 Financial Analysis
- 5.1.3 Regional Analysis
- 5.1.4 Research & Development Expense
- 5.2 AstraZeneca PLC
- 5.2.1 Company Overview
- 5.2.2 Financial Analysis
- 5.2.3 Regional Analysis
- 5.2.4 Research & Development Expenses
- 5.3 GlaxoSmithKline PLC (GSK)
- 5.3.1 Company Overview
- 5.3.2 Financial Analysis
- 5.3.3 Segmental and Regional Analysis
- 5.3.4 Research & Development Expense
- 5.4 Johnson & Johnson
- 5.4.1 Company Overview
- 5.4.2 Financial Analysis
- 5.4.3 Segmental &Regional Analysis
- 5.4.4 Research & Development Expenses
- 5.5 Ironwood Pharmaceuticals, Inc.
- 5.5.1 Company Overview
- 5.5.2 Financial Analysis
- 5.5.3 Regional Analysis
- 5.5.4 Research & Development Expenses
- 5.6 Eisai Co., Ltd.
- 5.6.1 Company Overview
- 5.6.2 Financial Analysis
- 5.6.3 Segmental and Regional Analysis
- 5.6.4 Research & Development Expenses
- 5.7 Medigus Ltd.
- 5.7.1 Company Overview
- 5.7.2 Financial Analysis
- 5.7.3 Segmental and Regional Analysis
- 5.7.4 Research & Development Expenses
- 5.8 Sebela Pharmaceuticals
- 5.8.1 Company Overview
- 5.8.2 Recent strategies and developments:
- 5.8.2.1 Partnerships, Collaborations, and Agreements:
- 5.9 Phathom Pharmaceuticals, Inc.
- 5.9.1 Company Overview
- 5.9.2 Research & Development Expenses
- 5.9.3 Recent strategies and developments:
- 5.9.3.1 Partnerships, Collaborations, and Agreements:
- 5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- 5.10.1 Company Overview
- 5.10.2 Recent strategies and developments:
- 5.10.2.1 Product Launches and Product Expansions:
LIST OF TABLES
- TABLE 1 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 2 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 3 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 4 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 5 Europe Antacids Market by Country, 2018 - 2021, USD Million
- TABLE 6 Europe Antacids Market by Country, 2022 - 2028, USD Million
- TABLE 7 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
- TABLE 8 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
- TABLE 9 Europe H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
- TABLE 10 Europe H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
- TABLE 11 Europe Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
- TABLE 12 Europe Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
- TABLE 13 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
- TABLE 14 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
- TABLE 15 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 16 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 17 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 18 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 19 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 20 UK Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 21 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 22 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 23 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 24 France Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 25 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 26 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 27 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 28 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 29 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 30 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 31 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 32 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 33 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 34 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 35 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 36 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 37 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 38 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 39 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
- TABLE 40 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
- TABLE 41 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
- TABLE 42 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
- TABLE 43 Key Information - Takeda Pharmaceutical Company Limited
- TABLE 44 KEY INFORMATION - AstraZeneca PLC
- TABLE 45 Key Information - GlaxoSmithKline PLC
- TABLE 46 Key information -Johnson & Johnson
- TABLE 47 Key Information - Ironwood Pharmaceuticals, Inc.
- TABLE 48 Key Information - Eisai Co., Ltd.
- TABLE 49 Key Information - Medigus Ltd.
- TABLE 50 Key Information - Sebela Pharmaceuticals
- TABLE 51 Key Information - Phathom Pharmaceuticals, Inc.
- TABLE 52 Key Information - Camber Pharmaceuticals, Inc.
List of Figures
- FIG 1 Methodology for the research
